Difficult-to-treat basal cell cancer: therapeutic possibilities in the era of targeted therapies

Abstract

Basal cell carcinoma is a common skin cancer with various risk factors. Treatment options include surgery, chemotherapy, and targeted therapy. HH pathway inhibitors have become integral in managing difficult-to-treat BCC. Sonidegib is a safe and effective drug with mild to moderate side effects, and immune checkpoint inhibitors are an alternative treatment for advanced BCC patients.